INESSS
Author: Patrick Manfred, Vice-President, TACT Conseil, Quebec Market Access Expert Date: June 2, 2021 A proposal to modify the current regulation framing the fees payable to the Institut national d'excellence en santé (INESSS) to complete a scientific evaluation of a drug and/or a stable blood product was published in Part 2 of the Quebec Official Gazette, on March 18, 2021. If the Quebec government does not deviate from…
Toronto, May 4th, 2021 – MORSE Consulting is pleased to release their 2021 edition of the Canadian Reimbursement and Forecasting Timelines (CRaFT) report - a comprehensive source of reimbursement timelines and insights to inform forecasting and planning needs. MORSE has analyzed Canadian market access data from 2018 through 2020 to produce key reimbursement metrics. The report will support forecasting or planning necessary for launch in Canadian by providing critical insights on the public…
Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders. What’s New in the April 2020 Update?…
Summary of CADTH Drug Portfolio Information Session Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the following sections: Welcome and Strategic Overview…
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can be a valuable education tool for…
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant - IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The purpose of this summary is two-fold:…
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency of CADTH’s Review Reports and Recommendations…
Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar Signals Decoded: Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs…
Aligned Reviews Between Health Canada (HC) and Health Technology Assessment Organizations (HTAs) Date: September 26th, 2018 Time: 10:00 AM - 11:30 AM Presenters: Alex Chambers (CADTH), Virginie Landreville (INESSS), M Coyer (HC), and T Richter (CADTH) Purpose: To describe the HC-HTA (CADTH and INESSS) aligned review process in more detail, and discuss any questions regarding this initiative. This initiative aims to improve regulatory review in order to obtain more…
On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists.…
A Comparison of Proposed INESSS and Current CADTH Evaluation Fees On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d'excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining…
Quebec Panel On Tuesday, June 13, 2017, the Canadian Association for Healthcare Reimbursement (CAHR) held the Market Access 201 conference in Toronto. The theme for this conference was Parallel or Intersecting Paths, the Future of Public and Private Reimbursement in Canada which consisted of five fascinating panels focusing on key topics of interest to the Canadian pharmaceutical stakeholders. Over the coming weeks, MORSE will be releasing summaries for each…
INESSS Introduces New Pre-NOC and Biosimilar Guidance The Institut national d'excellence en santé et en services sociaux (INESSS) released its new submission guidelines on June 2nd, 2017. The guidelines, which are now effective, include revised and new Form applications and letter templates for drug submissions. The two major highlights relate to pre-NOC review and the introduction of new guidelines for biosimilar submissions. Pre-NOC Review Unlike the CADTH pre-NOC guidelines…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2026 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
INESSS - Info and details on - MORSE Consulting Inc.
